Pharmacist Digest

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT

DECEMBER 8, 2023

Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines. The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. In 2017, he was elevated to CEO.

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT

DECEMBER 11, 2023

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a proud parent. Boger, 72, founded Vertex in 1989 and served in various roles until 2017.

Labelling

From winning SCOPE's Site Innovation Award to patient engagement and tech advancement, a Q&A with Medidata

Outsourcing Pharma

MARCH 4, 2024

A Q&A session was held at SCOPE 2024 in Orlando, Outsourcing Pharma speaks with Kelly McGee, VP of decentralized clinical trials and patient registries, and Daniel Braga, VP of EHR and healthcare solutions.

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and challenges ahead

STAT

JULY 20, 2023

Seth Berkley, the soon-to-be former CEO of Gavi, the Vaccine Alliance, apologized for being a few minutes late jumping on a Zoom call. Berkley — one of the highest-profile proponents of vaccination on the planet — was under a denial-of-service attack.

Vaccines

Q&A with CDC Director Mandy Cohen: On communication, trust, and getting things done

STAT

JULY 26, 2023

The new director of the Centers for Disease Control and Prevention, Mandy Cohen, is only two weeks into her new job. But already she hears the clock ticking. president is sworn in. president is sworn in. If the 2024 election goes one way, her term could be extended — pending Senate confirmation. Read the rest…

Communication

Opinion: Q&A: Giving voice to patients navigating cancer, rare disease, and more

STAT

JULY 25, 2023

Health care is about many things — understanding and treating disease, practicing medicine, developing new drugs, inventing new medical devices. But at its core, it is about one thing only: the patients.

Diversity and Mentoring at BioPharmas: A C-Suite Q&A with Korn Ferry’s JT Saunders

PharmExec

JULY 21, 2023

In this latest Harvard Business School Healthcare Alumni Association Q&A, JT Saunders, Chief Diversity Officer at global consulting firm Korn Ferry, discusses diversity in pharma, as well as what mentors and mentees should be considering in the workplace.

Poxviruses, outbreaks, and Ebola: A Q&A with a retiring CDC expert on bad bugs

STAT

SEPTEMBER 20, 2022

In the last week of August, one of the world’s foremost poxvirus experts retired from the Centers for Disease Control and Prevention.

A Q&A with WHO’s Maria Van Kerkhove on Covid — and fatigue over the pandemic

STAT

SEPTEMBER 1, 2022

The World Health Organization’s technical lead for Covid-19, Van Kerkhove understands that the world is struggling with a lot right now. Plus, everyone just wants Covid to be in the rear-view mirror.

Vaccines

Q&A: Cell and gene therapy value assessments need a rework to allow access

Pharmaceutical Technology

APRIL 19, 2024

Paolo Morgese, vice president of European public affairs at the Alliance for Regenerative Medicine, discusses the barriers affecting access to gene therapies.

STAT+: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA

STAT

MARCH 7, 2023

BOSTON — FDA Commissioner Robert Califf said on Monday that it “bothers” him that Novo Nordisk, which makes an obesity medication, funded the development of obesity coursework for medical schools. Continue to STAT+ to read the full story…

Medical Schools

Medical Schools Pharmaceutical Companies Pharmaceutical Companies Drug Development

STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle

STAT

MAY 9, 2023

Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. But it will be a show.

Drug Pricing

Drug Pricing Diabetes

Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells

STAT

NOVEMBER 25, 2022

The first cells Siddhartha Mukherjee ever saw were T cells, pulled from a mouse spleen and plated onto the microscope slide, given chemicals to coax them to grow. When he looked down the scope, he was struck by the life in them, marveling at what he called their “inner glow and luminous fullness.” Read the rest…

Pharma, New York, and Investing: Q&A with Jennifer Hawks Bland

PharmExec

APRIL 30, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

BIG Change to the Real Life Pharmacology Podcast! Asthma Pharmacology Q&A With Clinical Pharmacist and Expert Beth Zerr, PharmD, BCACP

Med Ed 101

SEPTEMBER 24, 2023

Asthma Pharmacology Q&A With Clinical Pharmacist and Expert Beth Zerr, PharmD, BCACP appeared first on Med Ed 101. I’m so excited to try something different today and interview one of my great friends!

At-Home Patients and AI: Q&A with Riccardo Butta

PharmExec

APRIL 16, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Q&A: Univar Solutions - the importance and challenges of distributing and sourcing pharma ingredients

Outsourcing Pharma

DECEMBER 6, 2023

From its origins in ancient military time where the Romans and Greeks used logistics and distribution channels to supply their armies, to today's challenges with the supply chain for pharma ingredients, we enjoyed putting some questions to Univar Solutions, Myrna Wilson.

Q&A With Derron Stark, Managing Director of Strategy and Transactions at EY

PharmExec

NOVEMBER 1, 2023

Stark discusses pharma’s supply chain and the issues it is facing.

Opinion: The hospice industry needs major reforms. It should start with apologies

STAT

AUGUST 22, 2023

” We’d come to the Q&A part of the evening in an historic church in eastern Pennsylvania. “How has the clinical work you do affected you personally?” I smiled at the casually dressed older man who asked the question. I smiled at the casually dressed older man who asked the question.

Q&A: Dr. Daniel Hernandez, Director of Medical Affairs and Hispanic Outreach, Global Healthy Living Foundation

PharmExec

AUGUST 10, 2023

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

Q&A: How AI and ML are reshaping the research landscape

BioPharma Dive

MARCH 4, 2024

Panalgo’s Meg Richards and Mike Munsell discuss how AI and ML are transforming the healthcare research landscape.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

FEBRUARY 23, 2024

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are twenty-four patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA

PharmExec

APRIL 19, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

FEBRUARY 7, 2024

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are twenty-four patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

Adapting to Remote Workers and Services: Q&A with Rebecca Marquez, Director of Custom Research at PMMI

PharmExec

MARCH 29, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Navigating Health Insurance Coverage for Innovative and Specialty Drugs: Q&A With Maria Kirsch, President of Patients Services at EVERSANA

PharmExec

OCTOBER 2, 2023

Kirsch discusses the complexity of the drugs and the verification process, along with EVERSANA’s new platform, ACTICS eAccess.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

JANUARY 13, 2024

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

JANUARY 10, 2024

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

State of Financing Deals and Go-to-Market Strategy in Biotech: Q&A with Timothy Moore and Jack Mycka, Indegene

PharmExec

JANUARY 6, 2023

A chat with with Indegene's Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts and Jack Mycka, Vice President, Enterprise Medical Solutions and Emerging Biotech.

Digital Tools and Rising Biopharma Manufacturing Costs: Q&A with Barry Heavey, Supply Chain Lead at Accenture

PharmExec

MARCH 6, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

DECEMBER 21, 2023

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

Medical Research Network's Edward Triebell on the shifts and statistics in clinical research's digital trends

Outsourcing Pharma

NOVEMBER 8, 2023

Executive director of Medical Research Network's (MRN's) digital health, Edward Triebell, joined OSP for a Q&A where he shared some interesting shifts and statistics about digital trends in clinical research.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

DECEMBER 11, 2023

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

New patent for Kaleo Inc drug AUVI-Q

Drug Patent Watch

DECEMBER 8, 2023

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions. It is available from three suppliers.

Twitter to 'X' and the Evolving Social Media Landscape for Marketers: Q&A with Mikaela Walker, Marketing and Social Manager at Greater Than One

PharmExec

AUGUST 22, 2023

Amid Twitter's transformation into "X", social media expert Mikaela Walker weighs in on the rebrand's impact for pharma marketing, assesses ongoing brand safety risks, and highlights established social platforms and those gaining traction.

Normalizing Data with AI: Q&A with Andrew Anderson, VP of Innovation and Informatics Strategy at ACD/Labs

PharmExec

MARCH 8, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Q&A with Rocket Pharmaceutical's CTO Mayo Pujols and CEO Gaurav Shah

PharmExec

OCTOBER 24, 2022

Rocket Pharmaceutical's CEO and CTO spoke with Pharm Exec about adding a new position to the company's C-suite.

Generating Pharma’s AI: Q&A With Masanori Ito, Senior Director, Head of Enterprise Insights and Digital Solutions, Digital, Analytics, and Technology at Astellas

PharmExec

OCTOBER 27, 2023

Ito discusses how data-driven AI can be utilized by the pharma industry.

What Pharma Fears Most About AI

PharmExec

OCTOBER 4, 2023

In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.

Cell and Gene Therapy Outlook: Q&A with Fran Gregory, VP of Emerging Therapies, Cardinal Health

Pharmaceutical Commerce

JANUARY 22, 2024

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.

Gen AI and its use in medical devices and SaMD

Pharmaceutical Technology

MARCH 28, 2024

In an exclusive Q&A, SaMD solutions provider Huma tells us how AI is allowing clinicians to make better decisions and why the human factor will remain a critical element of healthcare. AI is fast becoming a valuable tool for developers of regulated health apps.

Q&A With Joe Schmidt, EVP, Head of Customer Services and Success at Medidata

PharmExec

NOVEMBER 2, 2023

Schmidt discusses the recent announcement that Medidata and the NCI extended their partnership an additional five years.

Customer Service

Strategies for Successful Manufacturing of Highly Potent Oral Solids

PharmaTech

APRIL 10, 2024

In this Q&A article, industry experts discuss some of the challenges in HPAPI drug product manufacturing and the key issues sponsors should consider when partnering with a contract development and manufacturing organization (CDMO).

EMA publishes updated Q&A for ICH M10

European Pharmaceutical Review

JANUARY 26, 2023

The European Medicines Agency (EMA) has published an updated Q&A document regarding ICH M10 ‘Bioanalytical Method Validation and Study Sample Analysis’. Implementation of the ICH M10 document The EU date of coming into effect of the core ICH M10 document and the corresponding Q&As was 21 January 2023.

Method Validation

Method Validation Documentation

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

Trending Sources

From winning SCOPE's Site Innovation Award to patient engagement and tech advancement, a Q&A with Medidata

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and challenges ahead

Q&A with CDC Director Mandy Cohen: On communication, trust, and getting things done

Opinion: Q&A: Giving voice to patients navigating cancer, rare disease, and more

Diversity and Mentoring at BioPharmas: A C-Suite Q&A with Korn Ferry’s JT Saunders

Poxviruses, outbreaks, and Ebola: A Q&A with a retiring CDC expert on bad bugs

A Q&A with WHO’s Maria Van Kerkhove on Covid — and fatigue over the pandemic

Q&A: Cell and gene therapy value assessments need a rework to allow access

STAT+: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA

STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle

Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells

Pharma, New York, and Investing: Q&A with Jennifer Hawks Bland

BIG Change to the Real Life Pharmacology Podcast! Asthma Pharmacology Q&A With Clinical Pharmacist and Expert Beth Zerr, PharmD, BCACP

At-Home Patients and AI: Q&A with Riccardo Butta

Q&A: Univar Solutions - the importance and challenges of distributing and sourcing pharma ingredients

Q&A With Derron Stark, Managing Director of Strategy and Transactions at EY

Opinion: The hospice industry needs major reforms. It should start with apologies

Q&A: Dr. Daniel Hernandez, Director of Medical Affairs and Hispanic Outreach, Global Healthy Living Foundation

Q&A: How AI and ML are reshaping the research landscape

New patent for Kaleo Inc drug AUVI-Q

Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA

New patent for Kaleo Inc drug AUVI-Q

Adapting to Remote Workers and Services: Q&A with Rebecca Marquez, Director of Custom Research at PMMI

Navigating Health Insurance Coverage for Innovative and Specialty Drugs: Q&A With Maria Kirsch, President of Patients Services at EVERSANA

New patent for Kaleo Inc drug AUVI-Q

New patent for Kaleo Inc drug AUVI-Q

State of Financing Deals and Go-to-Market Strategy in Biotech: Q&A with Timothy Moore and Jack Mycka, Indegene

Digital Tools and Rising Biopharma Manufacturing Costs: Q&A with Barry Heavey, Supply Chain Lead at Accenture

New patent for Kaleo Inc drug AUVI-Q

Medical Research Network's Edward Triebell on the shifts and statistics in clinical research's digital trends

New patent for Kaleo Inc drug AUVI-Q

New patent for Kaleo Inc drug AUVI-Q

Twitter to 'X' and the Evolving Social Media Landscape for Marketers: Q&A with Mikaela Walker, Marketing and Social Manager at Greater Than One

Normalizing Data with AI: Q&A with Andrew Anderson, VP of Innovation and Informatics Strategy at ACD/Labs

Q&A with Rocket Pharmaceutical's CTO Mayo Pujols and CEO Gaurav Shah

Generating Pharma’s AI: Q&A With Masanori Ito, Senior Director, Head of Enterprise Insights and Digital Solutions, Digital, Analytics, and Technology at Astellas

What Pharma Fears Most About AI

Cell and Gene Therapy Outlook: Q&A with Fran Gregory, VP of Emerging Therapies, Cardinal Health

Gen AI and its use in medical devices and SaMD

Q&A With Joe Schmidt, EVP, Head of Customer Services and Success at Medidata

Strategies for Successful Manufacturing of Highly Potent Oral Solids

EMA publishes updated Q&A for ICH M10

Stay Connected